Britain Approves Decapeptyl as Combo Treatment for Early Stage Breast Cancer

Britain Approves Decapeptyl as Combo Treatment for Early Stage Breast Cancer
Britain has approved Ipsen Pharmaceuticals’ Decapeptyl (triptorelin) in combination with tamoxifen or an aromatase inhibitor to treat pre-menopausal, early stage breast cancer patients. The approval came from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). It covers Decapeptyl’s use as an adjuvant therapy — that is, one that improves the effectiveness of other treatments. Fourteen other

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *